The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

J Hematol Oncol · 2015 · PMC4615363 · PMID 26483188

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As shown in Table 4 , concurrent treatment at higher doses of 8 and 32 μM LDE225 showed greatest sensitization by fold-shift in EC 50 values of 5-Aza, while sequential dosing showed a trend towards antagonism, at least in vitro.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.